Oliver Schon, an expert in antibody-based therapeutic development, has been named head of product development and chemistry, manufacturing and controls (CMC), at BiVictriX Therapeutics Plc, a UK developer of cancer therapies. Dr Schon obtained his PhD in cancer research at the University of Cambridge and completed his postdoc research in the laboratory of Nobel Prize laureate Gregory Winter. He started his career at Domantis Ltd, later acquired by GlaxoSmithKline Plc. He worked at GSK for more than 10 years, later joining Agenus Inc in the US.
BiVictriX Therapeutics announced the appointment on 14 September 2021.
Copyright 2021 Evernow Publishing Ltd.